Human CD37 Protein (CD3-HM237)
$243.00 – $810.00
KACTUS Biosystems Human CD37 Protein (CD3-HM237) (catalog No. CD3-HM237) is expressed from HEK293 with hFc tag at the N-Terminus.It contains Ala113-Asn240.
- Details & Specifications
- References
- More Offers
| Catalog No. | CD3-HM237 |
|---|---|
| Product Name | Human CD37 Protein (CD3-HM237) |
| Supplier Name | KACTUS Biosystems |
| Brand Name | KACTUS Biosystems |
| Synonyms | Tetraspanin-26; Tspan-26; CD37; CD37 molecule; GP52-40; MGC120234 |
| Species | Human |
| Source | HEK293 |
| Accession | P11049-1 |
| Product Tag | N-hFc |
| Biotinylated | no |
| Exact Sequence | Ala113-Asn240 |
| Molecular Weight | The protein has a predicted MW of 41.9 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result. |
| Form | Lyophilized |
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Endotoxin | Less than 1EU per μg by the LAL method. |
| Shipping | Shipped at ambient temperature. |
| Stability & Storage | '-20 to -80°C for 12 months as supplied from date of receipt.； -20 to -80°C for 3-6 months in unopened state after reconstitution.； 2-8°C for 2-7 days after reconstitution.； Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Note | Products will be shipped from the warehouse in Massachusetts. Promotion is running from time to time. Welcome to send a request for quote to message@sydlabs.com. |
| Order Offline | Syd Labs, Inc. 4 Avenue E, Hopkinton, MA 01748 USA. Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com |
Description
CD3-HM237: Human CD37 Protein (CD3-HM237)
CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients.
Please remember our product information: Human CD37 Protein (CD3-HM237) catalog number: CD3-HM237 KACTUS Biosystems